Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Maxcyte (MXCT) Current Leases (2020 - 2025)

Maxcyte (MXCT) has disclosed Current Leases for 6 consecutive years, with $1.3 million as the latest value for Q3 2025.

  • On a quarterly basis, Current Leases rose 44.87% to $1.3 million in Q3 2025 year-over-year; TTM through Sep 2025 was $1.3 million, a 44.87% increase, with the full-year FY2024 number at $864000.0, up 11.63% from a year prior.
  • Current Leases was $1.3 million for Q3 2025 at Maxcyte, roughly flat from $1.3 million in the prior quarter.
  • In the past five years, Current Leases ranged from a high of $1.3 million in Q3 2025 to a low of $152200.0 in Q3 2022.
  • A 5-year average of $709033.3 and a median of $657600.0 in 2021 define the central range for Current Leases.
  • Peak YoY movement for Current Leases: plummeted 73.41% in 2022, then soared 392.99% in 2023.
  • Maxcyte's Current Leases stood at $527200.0 in 2021, then crashed by 70.22% to $157000.0 in 2022, then surged by 392.99% to $774000.0 in 2023, then rose by 11.63% to $864000.0 in 2024, then skyrocketed by 52.08% to $1.3 million in 2025.
  • Per Business Quant, the three most recent readings for MXCT's Current Leases are $1.3 million (Q3 2025), $1.3 million (Q2 2025), and $1.3 million (Q1 2025).